BxPC-3 Cells

BxPC-3 cells, originating from the pancreatic adenocarcinoma of a 61-year-old female patient who underwent radiation and chemotherapy, have become a fundamental asset in cancer research, particularly for studying pancreatic ductal adenocarcinoma. The absence of the SMAD4/DPC4 protein due to homozygous deletions in BxPC 3 cells makes them an invaluable resource for research into pancreatic cancer’s genetic landscape.
Tumors grown from BxPC-3 cells in nude mice produce carcinoembryonic antigen, human pancreas cancer-associated antigen, human pancreas-specific antigen, and traces of mucin. This highlights the ability of the cell line to closely replicate the histopathological traits of the primary tumor. The production of mucinous tissues, in particular, underscores the cell line’s value for detailed pancreatic adenocarcinoma studies, reflecting the original tumor’s characteristics.
BxPC-3 cells’ significant expression of angiogenic factors such as interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE2) opens avenues for exploring angiogenesis in cancer progression and identifying potential therapeutic targets.
In summary, the pancreatic adenocarcinoma cell line BxPC-3 are pivotal in cancer research, especially for pancreatic ductal adenocarcinoma research. Their lack of SMAD4/DPC4 protein because of homozygous deletions and their ability to replicate the primary tumor’s histopathological features, including mucinous tissues, make them invaluable for studying the genetic landscape and pathology of pancreatic cancer.